Skip to main content

Table 4 Post-hoc analysis on main outcomes

From: Prophylactic metformin after antenatal corticosteroids (PROMAC): a double blind randomized controlled trial

 

Metformin n = 52

Placebo n = 51

p value

Primary outcome

First 24 hours

n = 47a

n = 49a

 

Hyperglycemia episodesb

 Non GDM

3.9 ± 1.4

4.0 ± 1.7

0.81

 GDM

3.9 ± 1.5

4.4 ± 1.6

0.40

Secondary outcomes

First 24 hours

 Hypoglycemia episodesc

   

 Non GDM

0.1 ± 0.2

0.2 ± 0.5

0.23

 GDM

0 ± 0

0.0 ± 0.0

0.48

Second 24 hours

n = 46a

n = 40a

 

Hyperglycemia episodesb

 Non GDM

1.0 ± 1.3

1.1 ± 1.0

0.83

 GDM

1.5 ± 1.0

1.8 ± 1.2

0.70

Hypoglycemia episodesc

 Non GDM

0.8 ± 0.9

0.6 ± 0.8

0.48

 GDM

0.4 ± 0.9

0.3 ± 0.6

0.27

Third 24 hours

n = 37a

n = 37a

 

Hyperglycemia episodesb

 Non GDM

0.5 ± 1.0

0.6 ± 0.8

0.94

 GDM

0.3 ± 0.7

0.7 ± 1.1

0.61

Hypoglycemia episodesc

 Non GDM

0.7 ± 0.9

0.8 ± 0.8

0.37

vGDM

0.9 ± 0.8

1.1 ± 0.9

0.43

Blood sugar profile points 4–9

 Hyperglycemic episodes

2.7 ± 1.5

3.1 ± 1.4

0.16

 

3 [2-4]

3 [2-4]

0.15

  1. Data expressed as mean ± standard deviation and number (%). Analyses by Student t test for comparison of means. P > 0.05 for all analyses
  2. aNumber of monitoring compliant patients included in analysis: compliance defined as at least four of the six pre or 2-hour post meal sugar capillary blood profile points done in the relevant 24-hour block of the 3-day trial period
  3. bHyperglycemia is defined as pre meal blood glucose level of ≥ 5.3 mmol/L and 2 hours post prandial/meal blood glucose of ≥ 6.7 mmol/L
  4. cHypoglycemia is defined as capillary blood glucose level ≤ 3.9 mmol/L